Paradigm Biocapital Advisors LP C4 Therapeutics, Inc. Transaction History

Paradigm Biocapital Advisors LP

  • $2.77 Billion
  • Q3 2024

Shares

3 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2022

Aug 15, 2022
SELL
$5.06 - $26.46 $2.16 Million - $11.3 Million
-426,347 Reduced 85.36%
73,149 $552,000
Q1 2022

May 16, 2022
BUY
$19.99 - $33.23 $4.81 Million - $8 Million
240,750 Added 93.04%
499,496 $12.1 Million
Q4 2021

Feb 14, 2022
BUY
$29.39 - $46.86 $7.6 Million - $12.1 Million
258,746 New
258,746 $8.33 Million

Others Institutions Holding CCCC

# of Institutions
130
Shares Held
63.5M
Call Options Held
670K
Put Options Held
54.8K
View Full List

About C4 Therapeutics, Inc.

CCCC Quotes by TradingView
  • Ticker CCCC
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 48,913,800
  • Market Cap $208M
  • Description
  • C4 Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel therapeutic candidates to degrade disease-causing proteins for the treatment of cancer, neurodegenerative conditions, and other diseases. Its lead product candidate is CFT7455, an orally bioavailable MonoDAC degrader of protein that is in Phase 1/2 trial targeting ...
More about CCCC
Track This Portfolio

Track Paradigm Biocapital Advisors LP Portfolio

Follow Paradigm Biocapital Advisors LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Paradigm Biocapital Advisors LP, based on Form 13F filings with the SEC.

News

Stay updated on Paradigm Biocapital Advisors LP with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email